ストックスクリーナーアプリを入手
12.17
11.86%
1.29
前日終値:
$10.88
開ける：
$11.23
24時間の取引高:
842.20K
Relative Volume:
2.16
時価総額：
$783.72M
収益：
$5.01M
当期純損益:
$-35.62M
株価収益率:
-12.10
EPS:
-1.0062
ネットキャッシュフロー:
$-33.55M
1週間 パフォーマンス:
-21.53%
1か月 パフォーマンス:
-18.87%
6か月 パフォーマンス:
-8.15%
1年 パフォーマンス:
+633.13%
1日の値動き範囲:
$11.23
$12.46
1週間の範囲:
$10.80
$16.73
52週間の値動き範囲:
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Compare ANL vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
12.17 | 783.72M | 5.01M | -35.62M | -33.55M | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-10 | 開始されました | Jefferies | Buy |
| 2026-06-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-05-28 | 開始されました | Oppenheimer | Outperform |
| 2026-03-20 | 開始されました | Leerink Partners | Outperform |
| 2026-02-13 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | 開始されました | H.C. Wainwright | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
すべてを表示
Adlai Nortye Ltd Adr (ANL) 最新ニュース
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab - GlobeNewswire Inc.
ADARx Pharmaceuticals, Inc. (ADRX) Stock Price & News - Syfe
Adlai Nortye director Ji Ping sells $83,150 in shares - Investing.com
Adlai Nortye director Ji Ping sells $83,150 in shares By Investing.com - Investing.com Nigeria
Adlai Nortye (NASDAQ: ANL) director lines up ADS sale - Stock Titan
Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale - Stock Titan
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Australia
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Canada
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - investing.com
Adlai Nortye (NASDAQ: ANL) Initiates Global Phase I Trial for AN4035 with Phase Ia Data Expected in Late 2027 - Kalkine Media
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - investing.com
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com Canada
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com UK
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com India
Adlai Nortye doses first patient in AN4035 cancer trial - Investing.com
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com UK
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Adlai Nortye (ANL) sets vote on new share authorization - Stock Titan
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Zacks Investment Research
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportComposite Profile - siam.in
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportComposite Profile - siam.in
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportTechnical Analysis Picks - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com Nigeria
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com Canada
Adlai Nortye Ltd Adr (ANL) 財務データ
収益
当期純利益
現金流量
EPS
Adlai Nortye Ltd Adr (ANL) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ji Ping | Director |
Sep 29 '26 |
Sale |
15.77 |
214 |
3,375 |
131,453 |
| Ji Ping | Director |
Sep 29 '26 |
Proposed Sale |
15.28 |
80,000 |
1,222,400 |
0 |
| Ji Ping | Director |
Sep 22 '26 |
Sale |
16.63 |
5,000 |
83,150 |
131,667 |
| Ye Xiaofeng | CFO |
Aug 26 '26 |
Sale |
14.25 |
5,667 |
80,755 |
147,757 |
| Ye Xiaofeng | CFO |
Aug 24 '26 |
Sale |
13.98 |
6,000 |
83,880 |
153,424 |
| LU YANG | CEO |
May 13 '26 |
Sale |
13.18 |
10 |
132 |
99,990 |
2.94%
大文字化:
|
ボリューム (24 時間):